Opdualag

Chemical Namenivolumab and relatlimab-rmbw
Dosage FormInjection (intravenous; 240 mg of nivolumab and 80 mg of relatlimab per 20 mL (12 mg and 4 mg per mL))
Drug ClassMonoclonal antibodies
SystemSkin
CompanyBristol-Myers Squibb
Approval Year2022

Indication

  • For the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma
Last updated on 4/27/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Opdualag (nivolumab and relatlimab) Prescribing Information. 2022Bristol-Myers Squibb Company Princeton, NJ
Document TitleYearSource
Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. 2022The New England Journal of Medicine